News Releases

REDWOOD CITY, Calif., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell-driven diseases such as chronic spontaneous urticaria (CSU) and

- EU Clinical Trials authorized for Phase 1b/2a SPOTLIGHT and BEACON studies of briquilimab in CIndU and CSU, respectively - Patient enrollment in Phase 1b/2a SPOTLIGHT study of briquilimab in CIndU expected to commence in first quarter of 2024, initial data readout in second half of 2024 - Initial

REDWOOD CITY, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) in mast cell-driven diseases such as chronic spontaneous urticaria (CSU) and